Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants

Next Previous
X
Search
Trial Profile

A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALVAC HIV vCP2438 (Primary) ; HIV envelope protein gp120 modulators; MF 59
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms HVTN107

    • Most Recent Events

    • 01 Mar 2024 Results of Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine , published in the PLOS Medicine
    • 07 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2019 Planned End Date changed from 30 Sep 2019 to 31 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top